Immune checkpoint inhibitor combinations across clinically distinct metastatic renal cell carcinoma populations with limited or heterogeneous trial evidence: a systematic review, evidence map, and meta-analysis.
Immune checkpoint inhibitor (ICI) combinations are standard for metastatic renal cell carcinoma (mRCC), but evidence is uneven across distinct populations. We searched PubMed, Embase and Cochrane CENTRAL through June 3, 2026, and synthesized original studies reporting efficacy or safety in non-clear cell RCC, brain, bo...